TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cynata Therapeutics Limited ( (AU:CYP) ) has issued an announcement.
Cynata Therapeutics Limited announced the completion of the final patient visit in its Phase 3 SCUlpTOR trial for CYP-004, targeting osteoarthritis of the knee. This milestone marks the end of a two-year follow-up period, with data analysis expected to conclude by Q2 2026. The trial, conducted in partnership with the University of Sydney, aims to assess whether CYP-004 can modify the disease and alleviate symptoms. Osteoarthritis represents a significant market opportunity, affecting 600 million people globally, and Cynata’s product could offer a less invasive alternative to current treatments.
More about Cynata Therapeutics Limited
Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company specializing in stem cell and regenerative medicine. The company focuses on developing therapies using its proprietary Cymerus™ platform, which utilizes induced pluripotent stem cells (iPSCs) to produce mesenchymal stromal cells (MSCs) at a commercial scale. This approach addresses the challenges of conventional MSC production, offering economic and consistent cell therapy products without the need for multiple donors.
YTD Price Performance: 6.25%
Average Trading Volume: 194,774
Technical Sentiment Signal: Buy
Current Market Cap: A$60.55M
Find detailed analytics on CYP stock on TipRanks’ Stock Analysis page.